[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evotec Se (EVO)

Evotec Se (EVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 697,282
  • Shares Outstanding, K 355,756
  • Annual Sales, $ 891,970 K
  • Annual Income, $ -117,120 K
  • EBIT $ -185 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.92
  • Price/Sales 0.79
  • Price/Cash Flow N/A
  • Price/Book 0.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 2
  • High Estimate $0.08
  • Low Estimate $-0.19
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.9500 +0.51%
on 07/17/26
2.9300 -33.11%
on 07/02/26
-0.6500 (-24.90%)
since 06/17/26
3-Month
1.9500 +0.51%
on 07/17/26
3.4100 -42.52%
on 04/23/26
-1.3000 (-39.88%)
since 04/17/26
52-Week
1.9500 +0.51%
on 07/17/26
4.4150 -55.61%
on 07/28/25
-2.2800 (-53.77%)
since 07/17/25

Most Recent Stories

More News
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook

D isclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014  

EVT : 27.10 (+0.04%)
EVO : 1.9600 (-0.51%)
Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics

SEATTLE and HAMBURG, Germany , June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN,...

EVO : 1.9600 (-0.51%)
Evotec Reports Results of the Annual General Meeting 2026

11.06.2026 / 15:30 CET/CEST The issuer is solely responsible for the content of this announcement.

EVT : 27.10 (+0.04%)
EVO : 1.9600 (-0.51%)
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025...

EVO : 1.9600 (-0.51%)
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs

EVO : 1.9600 (-0.51%)
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth

EVO : 1.9600 (-0.51%)
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April...

EVO : 1.9600 (-0.51%)
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Ongoing strategic partnership advances joint pipeline in neurodegeneration research

EVO : 1.9600 (-0.51%)
BMY : 60.74 (+0.38%)
Evotec Announces Change in Management Board

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025

EVO : 1.9600 (-0.51%)
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy

EVO : 1.9600 (-0.51%)

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 2.1028
2nd Resistance Point 2.0703
1st Resistance Point 2.0151
Last Price 1.9600
1st Support Level 1.9274
2nd Support Level 1.8949
3rd Support Level 1.8397

See More

52-Week High 4.4150
Fibonacci 61.8% 3.4734
Fibonacci 50% 3.1825
Fibonacci 38.2% 2.8916
Last Price 1.9600
52-Week Low 1.9500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.